Company Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies.
The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer.
It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers.
In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform.
The company was founded in 2010 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2010 |
| IPO Date | Mar 9, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 73 |
| CEO | Dr. Lan Huang Ph.D. |
Contact Details
Address: 100 Campus Drive, West Side, 4th Floor, Suite 410 Florham Park, New Jersey 07932 United States | |
| Phone | 646-528-4184 |
| Website | beyondspringpharma.com |
Stock Details
| Ticker Symbol | BYSI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001677940 |
| CUSIP Number | G10830100 |
| ISIN Number | KYG108301006 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lan Huang Ph.D. | Co-Founder, Chairman and Chief Executive Officer |
| Linqing Jia | Co-Founder |
| Dr. June Lu Ph.D. | Chief Scientific Officer |
| Stephen Kilmer | Head of Investor Relations |
| Gregg Russo | Senior Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 18, 2024 | 6-K | Report of foreign issuer |
| Feb 26, 2024 | 6-K | Report of foreign issuer |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 2, 2024 | 6-K | Report of foreign issuer |
| Jan 16, 2024 | 6-K | Report of foreign issuer |
| Jan 10, 2024 | 6-K | Report of foreign issuer |
| Dec 18, 2023 | 6-K | Report of foreign issuer |
| Oct 30, 2023 | 6-K | Report of foreign issuer |
| Oct 4, 2023 | 6-K | Report of foreign issuer |
| Sep 20, 2023 | 6-K | Report of foreign issuer |